Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 4;14(1):62.
doi: 10.1186/s13023-019-1037-1.

Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study

Collaborators, Affiliations

Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study

Marco Confalonieri et al. Orphanet J Rare Dis. .

Abstract

Background: Late-onset Pompe disease (LOPD) is a recessive disease caused by α-glucosidase (GAA) deficiency, leading to progressive muscle weakness and/or respiratory failure in children and adults. Respiratory derangement can be the first indication of LOPD, but the diagnosis may be difficult for pneumologists. We hypothesize that assessing the GAA activity in suspected patients by a dried blood spot (DBS) may help the diagnosis of LOPD in the pneumological setting.

Population and methods: We performed a multicenter DBS survey of patients with suspected LOPD according to a predefined clinical algorithm. From February 2015 to December 2017, 140 patients (57 ± 16 yrs., 80 males) were recruited in 19 Italian pneumological units. The DBS test was performed by a drop of blood collected on absorbent paper. Patients with GAA activity < 2.6 μmol/L/h were considered positive. A second DBS test was performed in the patients positive to the first assay. Patients testing positive at the re-test underwent a skeletal muscle biopsy to determine the GAA enzymatic activity.

Results: 75 recruited subjects had outpatient access, 65 subjects were admitted for an acute respiratory failure episode. Two patients tested positive in both the first and second DBS test (1.4% prevalence), and the LOPD diagnosis was confirmed through histology, with patients demonstrating a deficient GAA muscle activity (3.6 and 9.1 pmol/min/mg). A further five subjects were positive in the first DBS test but were not confirmed at re-test. The two positive cases were both diagnosed after hospitalization for acute respiratory failure and need of noninvasive ventilation. Most of the recruited patients had reduced maximal respiratory pressures (MIP 50 ± 27% and MEP 55 ± 27% predicted), restrictive pattern (FEV1/FVC 81.3 ± 13.6) and hypoxaemia (PaO2 70.9 ± 14.5 mmHg). Respiratory symptoms were present in all the patients, but only 48.6% of them showed muscle weakness in the pelvic girdle and/or in the scapular girdle (35.7%).

Conclusions: DBS GAA activity test may be a powerful screening tool among pneumologists, particularly in the acute setting. A simple clinical algorithm may aid in the selection of patients on which to administer the DBS test.

Keywords: Acute respiratory failure; Diagnosis; Late-onset Pompe disease; Noninvasive ventilation; Respiratory high dependency care unit.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Ethical approval was given by the C.E.R.U. Friuli-Venezia Giulia (ref.# 67/2014).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Clinical algorithm to select patients for DBS test

References

    1. Raben N, Plotz P, Byrne BJ. Acid-alpha-glucosidase deficiency (glycogenosis type II, Pompe disease) Curr Mol Med. 2002;2:145–166. doi: 10.2174/1566524024605789. - DOI - PubMed
    1. Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guidelines. Genetics Med. 2006;8:267–288. doi: 10.1097/01.gim.0000218152.87434.f3. - DOI - PMC - PubMed
    1. Manganelli F, Ruggiero L. Clinical features of Pompe disease. Acta Myol. 2013;32:82–84. - PMC - PubMed
    1. Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, et al. The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Gen Metabol. 2017;120:163–172. doi: 10.1016/j.ymgme.2016.12.004. - DOI - PubMed
    1. Winkel LP, Hagemans ML, Van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, et al. The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol. 2005;252:875–84. - PubMed

Publication types

MeSH terms

Substances